It starts with trust—building confidence in clinical decision-making for heart failure
Patients who present in the ED with acute undifferentiated dyspnea often are affected by comorbidities that cloud the diagnostic process. These comorbidities include advanced age, obesity, and chronic kidney disease, and they pose challenges for clinicians in search of timely, accurate diagnosis. Historically, ruling in or ruling out heart failure has involved laboratory testing, physical exams, and imaging.
Taken together, these observations led Brandon R. Allen, Professor of Emergency Medicine and Cardiology at the University of Florida, to ask: “What if we had a better biomarker or a better tool to drive rule-in and rule-out in a better way?”
In his ADLM 2026 presentation, “NT-proBNP in Heart Failure Patients with Complex Co-morbidities: Building Clinical Confidence Through Accuracy and Precision,” Dr. Allen explored the challenges present in heart failure diagnosis in the ED, the validation of NT-proBNP in the PRECISE HF trial, and the importance of trust in clinical results for the advancement of patient care.
“Patients expect all of us to make the right decisions,” he said. “the emergency physician also expects that the test being ordered will come back with a valid, precise, and accurate result.”
Clinically, this requires tests that measure true signal without noise or interference (valid), ensure reproducibility (precise), and promote clear rule-in and rule-out decision making (actionable).
BNP and NT-proBNP—clinical biomarkers to aid in heart failure diagnosis
B-type natriuretic peptide (BNP) and NT-proBNP are biomarkers that provide diagnostic insight to aid in heart failure diagnosis. While heart failure co-morbidities affect natriuretic peptide interpretation, NT-proBNP demonstrates greater sensitivity for early detection, higher bloodstream concentrations, longer half-life, and less susceptibility to guideline-directed and ARNi therapy effects compared to BNP.
Trust and clinical confidence in diagnostic solutions like NT-proBNP, however, are built through the validation of typical patient presentations and routine ED workflows.
In a series of questions, Dr. Allen explored what is needed for this type of validation: “Are we concordant? Is this real-world data? . . . How do we confirm that in routine workflows?” And, finally, “How does that turn into actionable diagnostic and decision-making that drives disposition?”
Validation—the key to trust and clinical confidence
In its evaluation of NT-proBNP, the PRECISE-HF trial helped answer these questions. The study enrolled 2,384 patients across 17 U.S. sites. Highlighted findings shared by Dr. Allen showed that NT-proBNP <300 ng/L rules out acute HF across all ages, with 96% sensitivity and 95% NPV, alongside age-specific rule-in thresholds. The diagnostic performance of NT-proBNP in renal impairment demonstrated age-stratified cut point held rule-in (78% PPV, 74% specificity).
Advancing toward a shared goal—shortening time to high-confidence clinical diagnosis and care
Dr. Allen emphasized that it is clinical validation and collaboration between clinicians and laboratories that allow evidence-based NT-proBNP thresholds to be embedded into common clinical pathways. Peer-reviewed evidence supports informed clinical action to align biomarker performance with patient needs and help to define testing criteria surrounding rule-in/rule-out decisions.
He concluded, “when everybody’s North Star is the patient,” it can lead to innovation, greater discussion, and change.
English